Trends and advances in tumor immunology and lung cancer immunotherapy

Journal of Experimental and Clinical Cancer Research

Volumn 35, Issue 1, 2016, Pages 1-13

  Aldarouish, Mohanad ^a   Wang, Cailian ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Cancer vaccines; Clinical trials; Immune checkpoint inhibitors; Immunotherapy; Lung cancer; Tumor immunology

Indexed keywords

ATEZOLIZUMAB; B7 ANTIGEN; BELAGENPUMATUCEL L; BMS 936559; CANCER VACCINE; CD86 ANTIGEN; CIMAVAX; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEATH RECEPTOR; DURVALUMAB; FAS LIGAND; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 3; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT VACCINE; STAT3 PROTEIN; TECEMOTIDE; TG 4010; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADAPTIVE IMMUNITY; ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC LYMPHOCYTE; DISEASE ERADICATION; DOWN REGULATION; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; INNATE IMMUNITY; LUNG CANCER; MACROPHAGE; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TREND STUDY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR IMMUNOLOGY; UPREGULATION; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; PROCEDURES; TREATMENT OUTCOME;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 84990829888     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-016-0439-3     Document Type: Review

References (111)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
2. Mazzone P, Mekhail T. Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists. Respir Med. 2012;106(4):473-92.
3. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786-92.
4. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-9.
5. Schuster M, Nechansky A, Kircheis R. Cancer immunotherapy. Biogeosciences. 2006;1(2):138-47.
6. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-74.
7. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? Clin Invest. 2008;118(6):1991-2001.
8. Liu Y, Zeng G. Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. Immunother. 2012;35(4):299-308.
9. Clark Jr WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. Natl Cancer Inst. 1989;81(24):1893-904.
10. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. Clin Oncol. 2007;25(18):2586-93.
11. Gonzalez-Rodriguez AP, Contesti J, Huergo-Zapico L, Lopez-Soto A, Fernandez-Guizan A, Acebes-Huerta A, et al. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51(10):1829-36.
12. Van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, et al. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. Immunol. 2004;173(11):6753-9.
13. Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol. 2010;10(6):403-14.
14. Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol. 1998;10(5):581-7.
15. Cullen SP, Martin SJ. Mechanisms of granule-dependent killing. Cell Death Differ. 2008;15(2):251-62.
16. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ. 2010;17(4):616-23.
17. Nagata S, Golstein P. The Fas death factor. Science. 1995;267(5203):1449-56.
18. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 2003;63(14):4095-100.
19. Stoelcker B, Ruhland B, Hehlgans T, Bluethmann H, Luther T, Mannel DN. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol. 2000;156(4):1171-6.
20. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-73.
21. Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6(4):345-52.
22. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007;19(6):362-71.
23. Végran F, Apetoh L, Ghiringhelli F. Th9 cells: a novel CD4 T-cell subset in the immune war against cancer. Cancer Res. 2015;75(3):475-9.
24. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells. Nat Immunol. 2009;10(8):864-71.
25. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29:621-63.
26. Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res. 2014;2:91-8.
27. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70(21):8368-77.
28. Ikeda H, Old LJ, Schreiber RD. The roles of IFN in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13(2):95-109.
29. Galaine J, Borg C, Godet Y, Adotévi O. Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines. 2015;3(3):490-502. Disis ML (Nora), ed.
30. Haabeth OW, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, et al. How Do CD4+ T cells detect and eliminate tumor cells that either Lack or express MHC class II molecules? Front Immunol. 2014;5:174.
31. Trapani JA, Davis J, Sutton VR, Smyth MJ. Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr Opin Immunol. 2000;12(3):323-9.
32. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNFrelated apoptosis-inducing ligand-deficient mice. Immunol. 2002;168(3):1356-61.
33. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. Intern Med. 2009;266(2):154-81.
34. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002;2(11):850-61.
35. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503-10.
36. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5(12):1260-5.
37. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res. 2003;90:127-56.
38. Gardai SJ, Bratton DL, Ogden CA, Henson PM. Recognition ligands on apoptotic cells: a perspective. Leukoc Biol. 2006;79(5):896-903.
39. Jeannin P, Jaillon S, Delneste Y. Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol. 2008;20(5):530-7.
40. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67(6):2649-56.
41. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. Exp Med. 2006;203(4):871-81.
42. Prehn RT. Analysis of antigenic heterogeneity within individual 3-methylcholanthrene-induced mouse sarcomas. Natl Cancer Inst. 1970;45(5):1039-45.
43. Wortzel RDC, Philipps HS. Multiple tumor-specific antigens expressed on a single tumour cell. Nature. 1983;304:165-7.
44. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol. 2013;171(1):36-45.
45. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400-4.
46. Derniame S, Vignaud JM, Faure GC, Bene MC. Alteration of the immunological synapse in lung cancer: a microenvironmental approach. Clin Exp Immunol. 2008;154(1):48-55.
47. Kida H, Ihara S, Kumanogoh A. Involvement of STAT3 in immune evasion during lung tumorigenesis. Oncoimmunology. 2013;2(1):e22653.
48. Salmon H, Donnadieu E. Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix. Oncoimmunology. 2012;1(6):992-4.
49. Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, Ferrone S. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother. 2006;55(8):891-9.
50. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. Immunol. 2002;168(9):4272-6.
51. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 Tcell infiltration into the tumor microenvironment. Cancer Res. 2012;72(4):876-86.
52. Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, Amani D. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer. 2012;77(2):306-11.
53. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6(6):e1792.
54. Sauce D, Almeida JR, Larsen M, Haro L, Autran B, Freeman GJ, Appay V. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS. 2007;21(15):2005-13.
55. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH. Regulation of PD-1, PDL1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003;33(10):2706-16.
56. Wölfle SJ, Strebovsky J, Bartz H, Sähr A, Arnold C, Kaiser C, et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol. 2011;41(2):413-24.
57. Vander Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643-7.
58. Brichard VG, Godechal Q. MAGE-A3-specific anticancer immunotherapy in the clinical practice. Oncoimmunology. 2013;2(10):e25995.
59. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. Clin Oncol. 2013;31(19):2396-403.
60. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(6):822-35.
61. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4(1):45-60.
62. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010;29(20):2893-904.
63. Tang CK, Apostolopoulos V. Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines. 2008;7(7):951-62.
64. Decoster L, Wauters I, Vansteenkiste JF. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Ann Oncol. 2012;23(6):1387-93.
65. Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res. 2007;13:s4652-4654.
66. Xia W, Wang J, Xu Y, Jiang F, Xu L. L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review. Thorac Dis. 2014;6(10):1513-20.
67. Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, et al. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer. 2001;3:49-57. discussion 58.
68. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, et al. Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non-Small-Cell Lung Cancer. Clin Oncol. 2005;23(27):6674-81.
69. Butts C, Maksymiuk A, Goss G, Soulieres D, Marshall E, Cormier Y, et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis. Thorac Oncol. 2007;2(8):s332-3.
70. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59-68.
71. Wakefield LM, Hill CS. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat Rev Cancer. 2013;13:328-41.
72. Tian M, Neil JR, Schiemann WP. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal. 2011;23:951-62.
73. Drabsch Y, ten Dijke P. TGF-beta signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012;31(3-4):553-68.
74. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25(3):435-57.
75. Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. Clin Oncol. 2006;10(24):4721-30.
76. Giaccone G, Bazhenova LA, Nemunaitis J, Tan ME, Ramlau JR, Heuvel MM, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015;51(16):2321-9.
77. Linggi B, Carpenter G. ErbB receptors: New insights on mechanisms and biology. Trends Cell Biol. 2006;16:649-56.
78. Kuykendall A, Chiappori A. Advanced EGFR mutation-positive Non-small-cell lung cancer: case report, literature review, and treatment recommendations. Moffitt Cancer Center. 2014;21(1):67-73.
79. Hirsch FR, Varella-García M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene. 2009;28 Suppl 1:S32-7.
80. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53(10 suppl):2379-85.
81. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. Clin Oncol. 2008;26:1452-8.
82. Limacher JM, Quoix E. TG4010 A therapeutic vaccine against MUC1 expressing tumors. OncoImmunology. 2012;1(5):791-2.
83. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med. 1998;4:43-9.
84. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011;12:1125-33.
85. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res. 2003;9(12):4296-303.
86. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-48.
87. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-6.
88. Funt SA, Page DB, Wolchok JD, Postow MA. CTLA-4 antibodies: new directions, new combinations. Oncology (Williston Park). 2014;28 Suppl 3:6-14.
89. Li L, Chao QG, Ping LZ, Xue C, Xia ZY, Qian D, Shi-ang H. The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC. Cancer Biother Radiopharm. 2009;24(3):357-67.
90. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. Clin Oncol. 2012;30(17):2046-54.
91. Zatloukal P, Heo DS, Park K, Kang J, Butts C, Bradford D, et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC). Clin Oncol. 2009;27(15S):8071. Abstract.
92. Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104-11.
93. Benjamin C, Creelan MD. Update on immune checkpoint inhibitors in lung cancer. Moffitt Cancer Center. 2014;21:1.
94. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
95. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64.
96. Ramsay AG. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 2013;162(3):313-25.
97. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682-7.
98. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. Exp Med. 2009;206(13):3015-29.
99. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced Non-small-cell lung cancer. Clin Oncol. 2015;33(18):2004-12.
100. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257-65.
101. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous Non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-39.
102. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-28.
103. Rizvi N, Garon E, Patnaik A, Gandhi L, Leighl N, Balmanoukian A, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). Clin Oncol. 2014;32:507s. suppl; abstract 800.
104. Gettinger S, Shepherd F, Antonia S, Brahmer J, Chow L, Juergens R, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. Clin Oncol. 2014;32:512s. suppl; abstract 8024.
105. Soria JC, Cruz C, Bahleda R, Delord JP, Horn L, Herbst RS, et al. Clinical activity, safety, and biomarkers of a PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur J Cancer. 2013;49:abstr 3408.
106. Spigel DR, Gettinger SN, Horn L, Herbst RS, Gandhi L, Gordon MS, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Clin Oncol. 2013;31:abstr 8008.
107. Besse B, Johnson M, Jänne PA. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Presented at: 2015 European Cancer Congress; September 25-29; Vienna, Austria. Abstract 16LBA.
108. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837-46.
109. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65.
110. Antonia S, Rizvi N, Brahmer J, Ou SH, Khleif SN, Hwu WJ, et al. Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Res. 2016;4:A047.
111. Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, Ballas M, et al. A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study. Clin Lung Cancer. 2016;17(3):232-6.